News & Events
Insight Genetics participated in a panel discussion on personalized medicine at the Life Science Tennessee Annual 2014 Conference and Venture Forum held at the DoubleTree Hotel in Nashville, Tenn., Oct. 20-22.
Diagnostics firm increases infrastructure to support rising industry demands for design and development of clinical trial assays and companion diagnostics.
Insight Genetics Inc., a molecular diagnostic company dedicated to improving the lives of cancer patients through advanced diagnostics, announced today that it has added six employees to its team, growing its expertise in scientific research and development and quality assurance.
Insight Genetics was on hand at the Drug Information Association’s (DIA) 50th Annual Meeting in San Diego from June 15-19, 2014. Building on efforts to transition academic discoveries into clinical diagnostics, the team presented a poster highlighting processes for implementing Next Generation Sequencing (NGS) assays for the identification of biomarkers driving non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). The poster described an efficient NGS assay validation process for clinical laboratory adoption using practical examples of a targeted DNA-based NSCLC panel and an RNAseq-based assay to stratify subsets of TNBC patients.